2008-10-21 00:24:03 -
www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/research/73a90c/the_cns_market_out) has announced the addition of the "The CNS Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities" report to their offering.
"The global CNS disorders market expanded by 8.0% from 2006, to reach total sales of $77.3bn in 2007. This growth has been primarily driven by treatments for AD, ADHD and Parkinson's Disease."
The CNS disorders market is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms continue to be favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs. High levels of
investment have contributed to a rich product pipeline, with an estimated 600 clinical candidates currently under development, and companies are widely engaged in licensing novel/clinically differentiated CNS products.
The sector has struggled recently however, with previously dominant product classes coming under increasing pressure from generic competition and safety concerns. 'The CNS Market Outlook to 2013' is a new report published by Business Insights that provides comprehensive coverage of the major markets within the global CNS disorders market, incorporating a detailed epidemiological analysis of major indications and key factors impacting their prevalence. This report profiles the factors and underlying trends shaping the market landscape and identifies the most promising areas of potential growth. Current leading brands of treatment within each indication are assessed and ten of the market's leading players are profiled. Sales forecasts for currently marketed and key pipeline products over the 2008-13 period are also provided. Discover the key trends and growth drivers of the CNS market, assess the competitive dynamics of leading companies and evaluate the future prospects of pipeline products with this report...
'The CNS Market Outlook to 2013' is a report published by Business Insights that provides detailed coverage of the major markets within the global market for CNS disorder treatments, incorporating a detailed epidemiological analysis of major indications and the key factors impacting their prevalence. This report profiles the factors and underlying trends shaping the market landscape and identifies the most promising areas of potential growth. Current leading brands of treatment are assessed and ten of the market's leading players are profiled. Sales forecasts for currently marketed and key pipeline products to 2013 are also provided.
Assess the competitive dynamics of leading companies and evaluate the future prospects of pipeline products within the CNS disorders market...
Use this new report to...
"Despite being highly genericized, the CNS disorders market is dominated by the sales of original brands. These accounted for $53.5bn, representing 66.9% of the CNS market in 2007. Licensed brands and other brands recorded approximately the same market share of 10.7% and 9.2% respectively..."
- Assess epidemiology, treatment trends and sales patterns for treatment markets including depression, schizophrenia, AD, migraine, epilepsy, PD, insomnia and ADHD across major countries including the UK, Japan, France, Germany, Italy, Spain and the US.
- Measure the market performance and strategic positioning of major CNS developers with this report's evaluation of the franchises and market shares of AstraZeneca, Eli Lilly, Eisai, Forest, GSK, J&J, Novartis, Pfizer, Sanofi Aventis and Wyeth.
- Understand the market dynamics of the global CNS disorders area and identify the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.
- Predict revenues for major currently marketed and pipeline CNS products over 2008-13, with this report's sales forecasts across major indications, treatment classes and company portfolios.
- Discover the strategies that offer the greatest success potential for CNS developers in the future and understand the challenges currently facing companies within this therapeutic area.
Some Key Findings from this Report
"The US market accounted for the bulk of global sales in 2007, with 59.0% or $46.4bn. Germany led the major EU markets with a global market share of 5%; equivalent to sales of $3.7bn for 2007. Italy made the smallest contribution of the seven major markets having achieved sales of $1.4bn in 2007..."
- The global CNS disorders market expanded by 8.0% from 2006, to reach total sales of $77.3bn in 2007. This growth has been primarily driven by treatments for AD, ADHD and Parkinson's Disease.
- Schizophrenia treatments held the largest share of the CNS market with a share of 26.8%, following sales of $20.7bn in 2007. Atypical antipsychotic products dominate the schizophrenia market, having accrued sales of $19.8bn in 2007.
- The global anti-Alzheimer's market expanded by 21.3% between 2006-2007, to record total sales of $5.6bn. Steady growth will continue over 2007-2013 due to growing patient numbers and the increasing level of R&D investment in disease-modifying agents.
- Depression and insomnia were the only two CNS segments to experience falling sales over 2006-2007, declining by 4.5% and 8.5% respectively. Blockbuster patent expires and the rise of generic competition have had a significant impact upon both markets.
- The ten leading companies represented 67.6% of the CNS disorders market in 2007. J&J currently leads the market with an 8.1% share, driven by Risperdal's impressive growth in antipsychotics.
Business Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions.
The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry.
Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.
Your Questions Answered:
"Tegretol registered 2007 sales of $404m, an increase of four percentage points over equivalent 2006 sales. However, Tegretol's sales have been growing at a slow rate, which is indicative of the high levels of competition from generics and more effective second-generation anticonvulsants..."
- What will be the major growth indications and drivers within the CNS market between 2008-13?
- What are the major current trends within indications including depression, schizophrenia, ADHD, migraine, epilepsy, PD, Alzheimer's disease and insomnia across the seven major markets?
- How have recent product launches from companies such as J&J, Eli Lilly, GSK and Pfizer performed?
- What is the forecast commercial potential of the most promising compounds in clinical development?
- Which major pipeline developments will shape future strategies?
- What is the forecast market size and growth rate of major CNS indications?
- How significant is the threat of generics to the CNS disorders market?
- How will the competitive landscape of major CNS indications change over 2008-13?
Key Issues Examined in this Report..
"Schizophrenia represents a significant market opportunity, with treatments currently dominated by the atypical antipsychotics. There remains potential for pipeline drugs with superior efficacy and side-effect profiles. Currently, there are 87 drugs in the pipeline, with the majority in the early stages of development..."
- Imminent patent expires. Several major products such as Pfizer's Zoloft and Sanofi-Aventis' Ambien have suffered sales losses due to generic competition and this trend is expected to continue through 2013 due to a number of upcoming high-profile patent expirations.
- CNS franchise challenges. Recent high-profile studies have prompted increased safety monitoring from regulatory agencies and raised doubts over the risk profiles of many established treatments. In response, regulatory bodies including the FDA have strengthened labeling and restricted access product classes with safety concerns.
- Alzheimer's market potential. Therapies indicated for the treatment of Alzheimer's disease have strong sales potential due to the high levels of unmet need and the absence of disease-modifying agents.
- Expanded label indications for antidepressants. Leading antidepressant producers are aggressively marketing their products in newly approved indications such as OCD, GAD and SAD in an effort to exploit the commercial opportunities created by label expansions.
Key Topics Covered:
Executive Summary
Chapter 1 Scope and methodology
Chapter 2 Overview and epidemiology of CNS disorders
Chapter 3 Global market analysis
Chapter 4 Pipeline analysis
Chapter 5 Competitive landscape
Chapter 6 Appendix
List of Figures
List of Tables
Companies Mentioned:
- Johnson & Johnson (J&J)
- Eli Lilly
- GlaxoSmithKline (GSK)
- Pfizer
- AstraZeneca
- Novartis
- Sanofi-Aventis
- Wyeth
- Forest
- Eisai
For more information visit
www.researchandmarkets.com/research/73a90c/the_cns_market_out
Source: Business Insights
Research and Markets
Laura Wood, Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com 
